Study guide
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B
Key Takeaways Explain This Topic AI
Phytonadione 1.0 mg intramuscularly into the vastus lateralis within 6 hours of birth prevents early, classic, and late vitamin K deficiency bleeding.
Late vitamin K deficiency bleeding occurs almost exclusively in exclusively breastfed infants who did not receive parenteral prophylaxis, and more than half of cases present as intracranial hemorrhage.
Oral vitamin K regimens are not FDA-approved, absorb erratically, and fail to reliably prevent late vitamin K deficiency bleeding.
Erythromycin ophthalmic ointment prevents gonococcal ophthalmia but does not prevent chlamydial conjunctivitis, which appears at 5 to 14 days and requires systemic macrolide therapy.
An infant born to an HBsAg-positive mother receives hepatitis B vaccine plus HBIG within 12 hours at two separate sites, preventing transmission in more than 95 percent of exposures.
Last updated: September 2026
The neonatal period encompasses vital preventive interventions and universal screening programs designed to intercept life-threatening disorders before irreversible injury occurs. The certified nurse-midwife (CNM) plays an indispensable role in administering routine pharmacologic prophylaxis, interpreting multi-tiered universal screening panels, counseling families on evidence-based care, and managing common metabolic and hematologic derangements. On the AMCB certification examination, candidates are tested rigorously on the pathogenesis of Vitamin K Deficiency Bleeding (VKDB), the Critical Congenital Heart Disease (CCHD) pulse oximetry algorithm, blood spot metabolic panels, the management of neonatal hypoglycemia, and the differential diagnosis and phototherapy thresholds for neonatal hyperbilirubinemia.
Standard Neonatal Prophylaxis
Within the first hours following delivery, every newborn should receive three standardized prophylactic interventions: parenteral vitamin K1, ophthalmic antibiotic ointment, and the initial hepatitis B immunization. Standard Post-Delivery Prophylaxis Bundle
- ├── 1. Vitamin K1 (Phytonadione) ──> 1 mg IM within 6 hr ──> Prevents Early, Classic & Late VKDB
- ├── 2. Erythromycin 0.5% Ointment ──> 1 cm ribbon each eye ──> Prevents Neisseria gonorrhoeae Ophthalmia
- └── 3. Hepatitis B Vaccine ──> 5 mcg IM within 24 hr ──> + HBIG within 12 hr if maternal HBsAg positive
- 1. Vitamin K1 (Phytonadione) Prophylaxis
Physiologic Rationale: Neonates are born functionally deficient in vitamin K. Placentally transferred vitamin K is minimal, the sterile neonatal intestinal tract lacks colonizing microflora capable of synthesizing menaquinones, and breast milk contains very low concentrations (1 to 3 mcg/L, compared to infant requirements of ~1 mcg/kg/day). Vitamin K is an essential cofactor for hepatic gamma-glutamyl carboxylase , which catalyzes the post-translational carboxylation of glutamic acid residues required for functional activation of clotting factors II (prothrombin), VII, IX, and X , as well as regulatory proteins C and S.
Dosing & Route: Phytonadione 1.0 mg Intramuscularly (IM) (0.5 mg IM for preterm infants <1,500 g) administered into the anterolateral thigh (vastus lateralis) within 6 hours of birth .
Vitamin K Deficiency Bleeding (VKDB) Syndromes:
Early VKDB (First 24 hours): Occurs in infants whose mothers took medications that interfere with vitamin K metabolism (e.g., anticonvulsants such as phenytoin, carbamazepine, phenobarbital; rifampin; isoniazid; or maternal warfarin). Presents with severe cephalic, intrathoracic, or intra-abdominal bleeding.
Classic VKDB (Days 2 to 7): Associated with delayed feeding or suboptimal intake. Presents with cutaneous bruising, gastrointestinal bleeding, persistent oozing from the umbilical cord stump, or prolonged bleeding following circumcision.
Late VKDB (Weeks 2 to 12, up to 6 months): Occurs almost exclusively in exclusively breastfed infants who did NOT receive parenteral vitamin K prophylaxis at birth . Over 50% of late VKDB cases manifest as catastrophic intracranial hemorrhage (ICH) , carrying a 20% mortality rate and leaving surviving infants with profound, permanent neurologic deficits.
Oral Vitamin K Limitations: Oral vitamin K regimens are NOT FDA-approved , have erratic gastrointestinal absorption, require strict multi-dose adherence over weeks, and fail to reliably prevent late VKDB . Intramuscular administration is the unequivocal standard of care endorsed by the AAP and ACNM.
2. Ophthalmic Erythromycin Ointment Prophylaxis
Clinical Objective: Universal ocular prophylaxis to prevent Ophthalmia Neonatorum (neonatal keratoconjunctivitis) caused by exposure to maternal cervicovaginal Neisseria gonorrhoeae during vaginal or cesarean delivery.
Administration: A 1 cm ribbon of 0.5% erythromycin ophthalmic ointment instilled into each lower conjunctival sac within 1 to 2 hours of birth . The medication should not be flushed from the eyes.
Critical Board Distinction: Erythromycin ophthalmic ointment is highly effective against N. gonorrhoeae (which can cause rapid corneal ulceration, globe perforation, and irreversible blindness within 24 to 48 hours), but it DOES NOT prevent neonatal chlamydial conjunctivitis caused by Chlamydia trachomatis . Chlamydial ophthalmia manifests later (5 to 14 days of life) and requires systemic oral macrolide therapy (erythromycin or azithromycin) to cure ocular infection and clear nasopharyngeal colonization, thereby preventing chlamydial interstitial pneumonitis.
3. Hepatitis B Virus (HBV) Immunoprophylaxis
Vertical transmission of hepatitis B from mother to infant carries a >90% risk of chronic lifelong HBV infection, cirrhosis, and hepatocellular carcinoma. Prevention relies on timely immunization based on maternal Hepatitis B surface Antigen (HBsAg) status:
Maternal HBsAg Status Required Neonatal Interventions & Timing Midwifery Administration Protocols
HBsAg-Negative Mother Monovalent Hepatitis B Vaccine (5 mcg / 0.5 mL IM) within 24 hours of birth Administer IM in the anterolateral vastus lateralis. (If medically unstable or birth weight <2,000 g, vaccine may be deferred until hospital discharge or 1 month of age).
HBsAg-Positive Mother Hepatitis B Vaccine (5 mcg IM) PLUS Hepatitis B Immune Globulin (HBIG 0.5 mL IM) Administer both within 12 hours of birth at two separate anatomical injection sites (e.g., right and left thighs). Prevents vertical transmission in >95% of exposed infants. Post-vaccination serology (anti-HBs and HBsAg) is obtained at 9 to 12 months.
HBsAg Unknown Mother Hepatitis B Vaccine within 12 hours of birth Draw maternal blood stat to determine HBsAg status. If mother tests positive, administer HBIG as soon as possible, no later than day 7 of life (for term infants ≥2,000 g). If infant is preterm/low birth weight (<2,000 g), administer HBIG within 12 hours without awaiting lab results.